Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Topics Mar 16 | 2026Structure’s Topline Ph2 Aleniglipron Data; Lilly Launches Zepbound KwikPen; Positive Topline Ph3 Finerenone FIND-CKD ResultsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Mar 13 | 2026ATTD 2026 Key Press Releases (March 13)Purchase Blast
$599
Posted in: Basal Insulin, Other, Topics Mar 13 | 2026ATTD 2026 Key Press Releases (March 12)Purchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 12 | 2026ATTD 2026 Key Press Releases (March 11)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Mar 10 | 2026Kailera Initiates Another Ph2 Ribupatide Study; Ascletis Reports Topline Ph2 Data; Laekna Announces Topline Ph1 Data; Glooko Connects with Roche’s CGM; SK pharmteco to Manufacture Long-Acting API for Current Lilly Product; Novo Acknowledges FDA Form 483Purchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 09 | 2026Novo and Hims Take Another Turn at a Partnership; AbbVie Reports Topline Ph1 Amylin Data; Regeneron & Hansoh Share Ph3 Olatorepatide China Results; Lilly Releases Statement on CMS Obesity BALANCE Model; Zepbound KwikPen Available on Amazon; Veru Enrolls First Patient in Ph2b PLATEAU Study; Sequel Expands AID Launch Purchase Blast
$599
Posted in: Other, Topics Mar 09 | 2026Thoughts on Ph2 ZUPREME-1 Data: Can Petrelintide Still Compete?Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 06 | 2026MiniMed Shares IPO Pricing; NMPA Approves Sciwind/Pfizer’s Ecnoglutide Injection in Obesity; Novo Appoints New SVPPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Mar 05 | 2026Topline Petrelintide Ph2 Results; Potential Brand Name for Orforglipron?; New Novo Ph1 Obesity Asset; Altimmune and Lexicon Q4 ’25 Earnings; Lilly Launches New DTE Platform; Tandem Mobi Now Available on AndroidPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 04 | 2026FDA Issues Warning Letters for Misleading Pharmaceutical Advertising; Veru Initiates Enobosarm Ph2b PLATEAU Study; Vanda Initiates Tradipitant Ph3 StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Mar 03 | 2026Senseonics Q4 ’25 Earnings; BI Terminates Ph2 MASH ProgramPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 02 | 2026Novo Expands Ireland Manufacturing Facility; QL Biopharm Raises $72M in Series CPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other, Topics Feb 27 | 2026Structure Q4 ’25 Earnings; February CHMP Meeting HighlightsPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Feb 27 | 2026Ionis, Wave, and MannKind Q4 ’25 Earnings; New Ph2 Olatorepatide Study; ACHIEVE-3 Full Results; MindRank Doses First Patient in Ph3 Oral GLP-1RA Study; Fractyl Completes Pivotal EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 25 | 2026FDA Approves Biocon’s Generic Saxenda; Novo Partners for Oral Peptide Development; Medtronic Launches MiniMed Go in EU; Bloom Doses First Patient in Ph1 Obesity Trial; BreezeBio Raises $60M in Series B; Verdiva Completes Ph2b Obesity Enrollment; MHRA Raids Illegal Manufacturing Facilities in UKPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 25 | 2026Obesity Power Rankings: Who Will Challenge Lilly and Novo? Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 24 | 2026Novo Reduces Semaglutide WAC Prices; Pfizer To Commercialize Ecnoglutide in China; Novo Ph2 GGG data; AbbVie Builds Out Obesity Manufacturing; Fortress Sells PRV; Alveus Closes $197M Series A; Beta Bionics FDA Warning Letter; Hims & Hers Q4 ’25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 23 | 2026Lilly Launches Zepbound KwikPen; Allurion Gains FDA Approval; Eversense 365 Launches with twiist AID System; February CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 23 | 2026Cagrisema Gets RedefinedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 20 | 2026Tandem Q4 ’25 Earnings; Verdiva Obesity Pipeline Purchase Blast